PUBLISHER: GlobalData | PRODUCT CODE: 1410820
PUBLISHER: GlobalData | PRODUCT CODE: 1410820
BCR-ABL Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on BCR-ABL Tests market for the year 2020 and beyond. Leukemia is a heterogeneous group of cancers that affects the blood and bone marrow. Two common subtypes are lymphocytic leukemia's and myeloid leukemia's, which derive from lymphoid cells and myeloid cells, respectively. Leukemia can progress rapidly (acute), or slowly (chronic), and is the primary cause of deaths from cancer in children and young adults under the age of 20 years. There is no standard staging system for leukemia; the disease as described as untreated, in remission, or recurrent.
BCR-ABL is a mutation, also known as the Philadelphia (Ph) chromosome, which is formed by a reciprocal chromosomal translocation of the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9. This translocation results in a BCR-ABL fusion gene and production of a fusion protein - a tyrosine kinase signaling protein this is constitutively active, causing cells to divide uncontrollably.
The BCR-ABL tests include BCR-ABL In Situ Hybridization (ISH), BCR-ABL Nucleic Acid Amplification (NAATs), BCR-ABL Next Generation Sequencing (NGS), BCR-ABL Sanger Sequencing, BCR-ABL Pyrosequencing and Cytogenetics tests.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are -
Currently marketed BCR-ABL tests and evolving competitive landscape -
Global, Regional and Country level market specific insights -
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Abbott Laboratories, Sysmex Corp, Bio-Techne Corp, Danaher Corp, Bio-Rad Laboratories Inc, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Takara Bio Inc, and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to-
Not Applicable
Not Applicable
Not Applicable